US Markets

Gilead shares rise after United States approves remdesivir as COVID-19 drug

Credit: REUTERS/Stephen Lam

Oct 23 (Reuters) - Shares of Gilead Sciences Inc GILD.O rose 6% on Friday after its antiviral drug, remdesivir, became the first and only approved treatment for COVID-19 in the United States.

The U.S. health regulator's approval on Thursday for its use in hospitalized patients came despite the World Health Organization last week saying the drug did not have a substantial effect on patients' length of hospital stay or chances of survival in a global trial.

The U.S. Food and Drug Administration's (FDA) backing signals its confidence in Gilead's U.S.-based study results, which showed the drug was able to cut time to recovery in patients, Piper Sandler analyst Tyler Van Buren said in a client note.

Remdesivir has been available under an FDA emergency use authorization since May, after a study led by the National Institutes of Health showed it reduced hospital stays by five days.

The drug, given intravenously, could generate over $1 billion in sales during the second half of the year at the current case rate, analyst Van Buren said.

Remdesivir, which will be sold under the brand name Veklury, costs $3,120 for a five-day treatment course, or $2,340 for government purchasers such as the Department of Veterans Affairs.

Shares of Gilead were up 5.67% at $64.11 before the bell.

Gilead's remdesivir gets U.S. FDA approval for hospitalized COVID-19 patients

WHO defends data after concluding Gilead's remdesivir flopped COVID trial

Gilead questions WHO study that cast doubts on drug's COVID-19 benefits

FACTBOX-Drugmakers rush to develop COVID-19 treatments

FACTBOX-Countries where remdesivir is approved or supported for treating COVID-19

(Reporting by Manojna Maddipatla in Bengaluru; Editing by Arun Koyyur)

((manojna.kalyani@thomsonreuters.com; +91 8061822700;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

GILD

Other Topics

BioTech Healthcare Coronavirus

Latest Markets Videos

    Reuters

    Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

    Learn More